2025 France Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 France Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in France include OSE Immunotherapeutics, Brenus Pharma, ImmunXperts SA, and Celentyx Ltd. OSE Immunotherapeutics, headquartered in Nantes, France, focuses on first-in-class immunotherapies for cancer and immunoinflammation, with products in clinical trials such as the Tedopi cancer vaccine and collaborations with Boehringer Ingelheim on SIRPα inhibitors. Brenus Pharma is developing off-the-shelf cancer immunotherapies targeting treatment resistance in solid tumors. ImmunXperts SA and Celentyx Ltd. are recognized key players globally in this market, providing specialized outsourcing services which likely extend to France, contributing to drug discovery advancements with technologies like monoclonal antibodies and oncolytic viral therapies.
These companies drive innovation in cancer immunotherapy through drug discovery outsourcing, providing specialized capabilities that reduce R&D costs while accelerating development timelines. OSE Immunotherapeutics also leads consortium projects funded by French public entities to develop mRNA therapeutics, addressing critical challenges in RNA delivery and manufacturing. Meanwhile, ImmunXperts SA and Celentyx Ltd. offer contract research services crucial for target identification, preclinical research, and clinical trial management, aligning with global market growth trends driven by AI/ML integration and rising demand for cancer immunotherapies. Collectively, these firms support France’s growing role in the cancer immunotherapy outsourcing market amid a global industry valued in the billions and expanding rapidly.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in France include OSE Immunotherapeutics, Brenus Pharma, ImmunXperts SA, and Celentyx Ltd. OSE Immunotherapeutics, headquartered in Nantes, France, focuses on first-in-class immunotherapies for cancer and immunoinflammation, with products in clinical trials such as the Tedopi cancer vaccine and collaborations with Boehringer Ingelheim on SIRPα inhibitors. Brenus Pharma is developing off-the-shelf cancer immunotherapies targeting treatment resistance in solid tumors. ImmunXperts SA and Celentyx Ltd. are recognized key players globally in this market, providing specialized outsourcing services which likely extend to France, contributing to drug discovery advancements with technologies like monoclonal antibodies and oncolytic viral therapies.
These companies drive innovation in cancer immunotherapy through drug discovery outsourcing, providing specialized capabilities that reduce R&D costs while accelerating development timelines. OSE Immunotherapeutics also leads consortium projects funded by French public entities to develop mRNA therapeutics, addressing critical challenges in RNA delivery and manufacturing. Meanwhile, ImmunXperts SA and Celentyx Ltd. offer contract research services crucial for target identification, preclinical research, and clinical trial management, aligning with global market growth trends driven by AI/ML integration and rising demand for cancer immunotherapies. Collectively, these firms support France’s growing role in the cancer immunotherapy outsourcing market amid a global industry valued in the billions and expanding rapidly.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
